

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5038360

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ASTRAZENECA UK LIMITED	06/22/2018
RECEIVING PARTY DATA		
Name:	ASTRAZENECA AB	
Street Address:	SE-151 85	
City:	SODERTALJE	
State/Country:	SWEDEN	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15363030
CORRESPONDENCE DATA		
Fax Number:	(301)576-6932	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	301-398-3199	
Email:	denise.cooper@astrazeneca.com	
Correspondent Name:	ASTRAZENECA PHARMACEUTICALS	
Address Line 1:	ONE MEDIMMUNE WAY	
Address Line 4:	GAITHERSBURG, MARYLAND 20878	
ATTORNEY DOCKET NUMBER:	200381-US-NP	
NAME OF SUBMITTER:	DENISE COOPER	
SIGNATURE:	/Denise Cooper/	
DATE SIGNED:	07/06/2018	
Total Attachments: 3		
source=6212445_1#page1.tif		
source=6212445_1#page2.tif		
source=6212445_1#page3.tif		

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of the **30th of November 2016** (the “Effective Date”) by and between

ASTRAZENECA UK LIMITED, a company incorporated in England and Wales under no. 3674842, with registered office address at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, England, CB2 0AA (“Assignor”); and


ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with registered office address at SE-151 85 Södertälje, Sweden (“Assignee”).

WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s legal right, legal title and legal interest in and to the patent applications identified in the attached Schedule (the “Applications”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. For good and valuable consideration made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “Rights”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.
5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.




Signed for and on behalf of
ASTRAZENECA UK LIMITED

Name: Christopher WINTER

Title: Authorised Signatory

Date 22 June 2018



Signed for and on behalf of
ASTRAZENECA AB

Name: Sally CURRAN

Title: Authorised Signatory

Date 22 June 2018

THE SCHEDULE

APPLICATIONS				
AstraZeneca Case No:	Country	Filing Type	Filing Date	Application No. and/or Title of Invention
200381-WO-PCT	International	PCT	30 Nov 2016	PCT/EP2016/079250
200381-AR-NP	Argentina	NP	30 Nov 2016	20160103663
200381-BO-NP	Bolivia	NP	30 Nov 2016	SP-278-2016
200381-BS-NP	Bahamas	NP	25 Apr 2017	2784
200381-ET-NP	Ethiopia	NP	29 Nov 2016	ET/P/16/349
200381-GC-GCP	GCC	GCP	29 Nov 2016	32456
200381-JM-NP	Jamaica	NP	21 Dec 2016	18/1/5788
200381-LB-NP	Lebanon	NP	29 Nov 2016	11067
200381-PK-NP	Pakistan	NP	29 Nov 2016	751/2016
200381-TW-NP	Taiwan	NP	29 Nov 2016	105139337
200381-US-NP	US	NP	29 Nov 2016	15/363030
200381-VE-NP	Venezuela	NP	30 Nov 2016	000589-2016

Priority Applications

AstraZeneca Case No:	Country	Filing Type	Filing Date	Application No. and/or Title of Invention
200381-US-PSP	US	PSP	30 Nov 2015	62/260789